Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria

The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research... Diffuse low-grade gliomas (LGG) are rare tumors that affect young adult patients. The European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) have both developed their own clinical prognostic scores to assist clinicians in treatment decision-making. These criteria have been used to include patients in phase III studies. To date, it is unknown which is the best score to define the prognosis of LGG. Additionally, a pure clinical classification is probably not a sufficiently informative basis for choosing the proper treatment in different situations. A combined score with both clinical and molecular features will likely be indispensable. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/the-risk-assessment-in-low-grade-gliomas-an-analysis-of-the-european-ruQbjsK5YP
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0063-9
Publisher site
See Article on Publisher Site

Abstract

Diffuse low-grade gliomas (LGG) are rare tumors that affect young adult patients. The European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) have both developed their own clinical prognostic scores to assist clinicians in treatment decision-making. These criteria have been used to include patients in phase III studies. To date, it is unknown which is the best score to define the prognosis of LGG. Additionally, a pure clinical classification is probably not a sufficiently informative basis for choosing the proper treatment in different situations. A combined score with both clinical and molecular features will likely be indispensable.

Journal

Oncology and Therapy – Springer Journals

Published: Jul 16, 2018

References

  • Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation
    Rees, J; Watt, H; Jäger, HR
  • Addressing diffuse glioma as a systemic brain disease with single-cell analysis
    Sahm, F; Capper, D; Jeibmann, A
  • Surgery insight: the role of surgery in the management of low-grade gliomas
    Pouratian, N; Asthagiri, A; Jagannathan, J
  • The 2007 WHO classification of tumours of the central nervous system
    Louis, David N; Ohgaki, Hiroko; Wiestler, Otmar D
  • Improving diagnostic accurancy and interobserver concordance in the classification and grading of primary gliomas
    Coons, SW; Johnson, PC; Scheithauer, BW
  • The 2016 World Health Organization classification of tumors of the central nervous system: a summary
    Louis, DN; Perry, A; Reifenberger, G
  • Prognostic factors for survival in adult patients with cerebral low-grade glioma
    Pignatti, F; Bent, M; Curran, D
  • A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844
    Karim, ABMF; Maat, B; Hatlevoll, R
  • Randomized trial of the efficacy of radiotherapy for low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BR04: an interim analysis
    Karim, ABMF; Afra, D; Cornu, P
  • Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial
    Shaw, EG; Berkey, B; Coons, SW
  • Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma
    Buckner, JC; Shaw, EG; Pugh, SL
  • Supratentorial low-grade glioma in adults: an analysis of prognostic factors and the timing of radiation
    Leighton, C; Fisher, B; Bauman, G
  • Role of extent of resection in the long term outcome of low-grade hemispheric glioma
    Smith, JS; Chang, EF; Lamborn, KR
  • Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables
    Shibamoto, Y; Kitakabu, Y; Takahashi, M
  • Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study
    Baumert, BG; Hegi, ME; Bent, MJ
  • The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis
    Wijnenga, MMJ; French, PJ; Dubbink, HJ